Kemo Sabe
Kemo Sabe is a privately-held, principal-led MedTech commercialization advisory firm that helps healthcare entrepreneurs, corporate intrapreneurs, and investors de-risk and accelerate medical technology products to market via its Assess-Define-Accelerate framework.
- Company typePrivate
- Founded2016
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Kemo Sabe does
Kemo Sabe is a privately-held, principal-led MedTech commercialization advisory firm that helps medical technology clients identify strategic blind spots, de-risk commercialization operations, and accelerate time-to-market for new products. Its core service offering is a structured three-stage methodology — Assess, Define, Accelerate — covering strategic gap analysis, business model and product positioning validation, and tactical market acceleration including team building, funding quantification, and roadmap development. The firm targets three client types: MedTech entrepreneurs optimizing technology commercialization, intrapreneurs inside established healthcare organizations launching new products or business models, and investors performing diligence on healthcare innovation opportunities. Named public clients include Novartis Neuroscience and UNYQ, a 3D-printed custom orthopedic and prosthetic devices company.
The practice is led by Lisa Tweardy (Principal), who holds 19 patents, has published in Spine and The Journal of Neurosurgery, and previously served as CEO of Combat Medical, General Manager of Biomet Bracing, and VP/GM Spine at Ossur. Delivery capacity is supplemented by an extended bench of contributors: Eric Gorman (design sprints and innovation facilitation via Wily), Kevin Lozeau (30 years of new-product development and industrial design across consumer electronics, health, and packaged goods), and Sasha Cahill (serial MedTech entrepreneur focused on AI-enabled healthcare technology). The firm operates digitally from humavericks.com with a quote-based, project-based professional services model and direct client engagement; pricing is not publicly disclosed and no funding has been raised. Geographic footprint is stated as global with US anchoring, and there are no offices, subsidiaries, or investors disclosed in the input data.
Kemo Sabe firmographics
Firmographics- Name
- Kemo Sabe
- Legal name
- Kemo Sabe
- Website
- https://humavericks.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Kemo Sabe is a privately-held, principal-led MedTech commercialization advisory firm that helps healthcare entrepreneurs, corporate intrapreneurs, and investors de-risk and accelerate medical technology products to market via its Assess-Define-Accelerate framework.
- Ownership category
- akta.pro rank
Kemo Sabe industry classification
Industry- Product category
- Healthcare Management Consulting
- NAICS
- Management Consulting Services (54161)
- SIC
- Services-Management Consulting Services (8742)
- akta.pro primary industry
- Corporate Strategy Advisory (BPAHADAA)
Keywords
Kemo Sabe business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations, Others
Revenue model
- Advisory and Consulting Services: Kemo Sabe provides strategic consulting services to MedTech companies, helping clients identify blind spots, de-risk operations, and accelerate commercialization. The firm works with entrepreneurs, intrapreneurs, and investors in the healthcare innovation ecosystem.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Kemo Sabe product offering
Product offeringCore offering
Kemo Sabe is a MedTech commercialization advisory practice that helps healthcare technology companies bring products to market faster and with less risk. Using a three-stage Assess-Define-Accelerate methodology, the firm provides strategic consulting to MedTech entrepreneurs, corporate intrapreneurs, and investors evaluating healthcare innovations. The practice is led by Principal Lisa Tweardy, who brings 30+ years of MedTech experience and 19 patents in the field.
Product overview
Kemo Sabe is a MedTech commercialization advisory firm offering a three-stage process framework (Assess, Define, Accelerate) to help medical technology companies bring products to market faster with reduced risk. Services target entrepreneurs developing new medical technologies, intrapreneurs within established healthcare organizations, and investors evaluating MedTech opportunities. The firm is led by Lisa Tweardy as Principal, with expertise spanning neuroscience, orthopedic and prosthetic devices, and AI-enabled healthcare technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Assess Process
Companies that use Kemo Sabe
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Kemo Sabe technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kemo Sabe partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Kemo Sabe competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key risks4 records
Key highlights5 records
Customer concentration
Kemo Sabe financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kemo Sabe leadership team
Management profileNumber of profiles
Profiles4 records
Kemo Sabe funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kemo Sabe M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kemo Sabe
What does Kemo Sabe do?
Kemo Sabe is a MedTech commercialization advisory practice that helps healthcare technology companies bring products to market faster and with less risk. Using a three-stage Assess-Define-Accelerate methodology, the firm provides strategic consulting to MedTech entrepreneurs, corporate intrapreneurs, and investors evaluating healthcare innovations. The practice is led by Principal Lisa Tweardy, who brings 30+ years of MedTech experience and 19 patents in the field.
Is Kemo Sabe a public or private company?
Kemo Sabe is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Kemo Sabe founded?
Kemo Sabe was founded in 2016. It employs 1 to 10 people.
How does Kemo Sabe make money?
One revenue line is on record: advisory and Consulting Services.
Does Kemo Sabe have an API?
No public API is recorded for Kemo Sabe.
What industry is Kemo Sabe in?
Kemo Sabe's product category is Healthcare Management Consulting. Its primary akta.pro industry code is BPAHADAA, Corporate Strategy Advisory. Its NAICS code is 54161 and its SIC code is 8742.